Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Serplulimab plus Chemotherapy in Resectable NSCLC
NCT05775796Phase 2Completed
- Sponsor
- Fudan University
- Start
- Mar 2023
- Primary completion
- May 2024
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of serplulimab in non-small cell lung cancer (NSCLC), sponsored by Fudan University. Started Mar 2023; status: completed.
02
Drugs
serplulimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05775796.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05775796.